Evidence map›Paper›PMID 37460203›Full record

ArticleJournal of medical genetics2023

A multilayered approach to the analysis of genetic data from individuals with suspected albinism.

Panagiotis I Sergouniotis, Vincent Michaud, Eulalie Lasseaux, Christopher Campbell, Claudio Plaisant, Sophie Javerzat, Ewan Birney, Simon C Ramsden, Graeme C Black, Benoit Arveiler

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Panagiotis I SergouniotisDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK panagiotis.sergouniotis@manchester.ac.uk benoit.arveiler@chu-bordeaux.fr graeme.black@manchester.ac.uk.ORCID 0000-0003-0986-4123
Vincent MichaudDepartment of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.ORCID 0000-0002-5788-392X
Eulalie LasseauxDepartment of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.
Christopher CampbellManchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Claudio PlaisantDepartment of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.
Sophie JaverzatINSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.
Ewan BirneyEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL- EBI), Wellcome Genome Campus, Cambridge, UK.
Simon C RamsdenManchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Graeme C Black *Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK panagiotis.sergouniotis@manchester.ac.uk benoit.arveiler@chu-bordeaux.fr graeme.black@manchester.ac.uk.
Benoit Arveiler *Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France panagiotis.sergouniotis@manchester.ac.uk benoit.arveiler@chu-bordeaux.fr graeme.black@manchester.ac.uk.
Université de Bordeaux · FREuropean Bioinformatics Institute · GBManchester University NHS Foundation Trust · GBUniversity of Manchester · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Albinism is a clinically and genetically heterogeneous group of conditions characterised by visual abnormalities and variable degrees of hypopigmentation. Multiple studies have demonstrated the clinical utility of genetic investigations in individuals with suspected albinism. Despite this, the variation in the provision of genetic testing for albinism remains significant. One key issue is the lack of a standardised approach to the analysis of genomic data from affected individuals. For example, there is variation in how different clinical genetic laboratories approach genotypes that involve incompletely penetrant alleles, including the common, 'hypomorphic'

Indexed as

AlbinismAlbinism, OculocutaneousAllelesGenetic TestingGenotypeHumansGenetics, MedicalGenetic TestingOphthalmology

Identifiers

PMID37460203
PMCPMC10715518
OpenAlexW4384521808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.